Understanding how different markets and product types shape pricing, reimbursement, and access strategies.

Global Market Access Models (Short “How It Works” Overviews)

United States

• Pricing freedom with strong payer controls. The U.S. does not use international reference pricing; instead, access is shaped by private and public payer policies and negotiation.
• Formulary access, benefit design, and utilization management are decisive. Pharmacy benefit managers (PBMs) influence formularies and may favor higher-rebate products, affecting affordability and access.
• Independent value assessors inform, but don’t mandate, decisions. Large insurers conduct their own assessments; ICER publishes value reviews that stakeholders use in pricing and coverage deliberations.
• Practical implication for launch teams: expect complex benefit designs and increasingly sophisticated UM; plan early to navigate these constraints. 

Europe / HTA-driven systems (conceptual)

• Early benefit and economic value testing. Most European systems link reimbursement and price to comparative clinical value and cost-effectiveness (often expressed as cost per QALY).
• Price–volume and affordability dynamics. Negative HTA opinions can translate into price cuts, price-volume agreements, restricted reimbursement levels, or tighter prescribing scope.
• National vs. regional layers. Many countries have a national payer with possible regional layers or mixed public/private payers; arguments that work in one setting may not in another.
• Example — UK: NICE has historically referenced a deliberative threshold range of ~£20,000–£30,000 per QALY.
• Example — France: Reimbursement level (SMR) and clinical added value (ASMR) drive coverage and the price negotiation with CEPS, alongside CEESP’s economic opinion. 

Japan (and other major markets, conceptually)

• National fee schedule and listing. After PMDA approval, products are listed on the National Health Insurance (NHI) “drug price standard,” which sets reimbursed prices.
• Periodic price revisions. Japan surveys market transaction prices and revises NHI prices regularly (historically on a two-year cycle, with additional “off-year” mechanisms).
• Cost-effectiveness as a price-adjustment tool. Cost-effectiveness evaluations inform post-listing price adjustments, using reference values around ¥5–10m per QALY (with higher references for special categories).
• Example — China (illustrative of “other major markets”): HTA for NRDL negotiations considers comparators, CEA, and budget impact; willingness-to-pay levels are used in practice, though official thresholds are not published. 

Tip for the paper layout: render each “spotlight” as a half-page box with (i) who decides, (ii) how price is set, (iii) what evidence matters most, and (iv) practical launch implications for teams in that market.

Therapeutic Archetypes & Access Implications

Why one-size-fits-all fails

Market access levers, stakeholders, and payer concerns vary by product type; bespoke, archetype-based planning improves launch execution. 

The five archetypes (and what changes)

Vaccines

• Evidence & policy: Engage CDC/ACIP and guideline bodies; plan for varying recommendation outcomes and incorporate public-health value in your narrative.
• Channel & fulfillment: Coordinate closely with manufacturing/supply chain and tailor channel strategies across retail, health systems, and public-health entities.
• Contracting & payment: Emphasize population-level value and coverage clarity for large cohorts. 

General Medicine (e.g., cardiometabolic, respiratory)

• Evidence: Pragmatic outcomes and adherence/real-world performance can matter where individual budgets are tight and volumes large.
• Contracting: Value-based agreements can be challenging at low price points and with diffuse outcomes; population-based approaches work better than heavy patient-level monitoring.
• Channel: Optimize benefit assignment (pharmacy), formulary positioning, and affordability solutions at scale. 

High-Volume Specialty (e.g., MS, immunology, hepatitis C)

• Evidence: Define comparative effectiveness and appropriate utilization up front; plan for indication sequencing.
• Channel & payment: Decide early on pharmacy vs. medical benefit assignment and integrate hub/patient services with field reimbursement support.
• Contracting: Balance speed to access with gross-to-net preservation; choose traditional vs. innovative contracts by payer segment.

Oncology

• Evidence: Align with guideline bodies and KOLs; consider endpoints not fully captured in trials (e.g., OS), combination therapies, and biomarker/diagnostic pathways.
• Access execution: Map patient OOP drivers across the full care pathway and coordinate trade/channel partners for site-of-care complexity.
• Policy influence: Early market shaping and education on disease burden and long-term impact can support access.

Rare Disease (incl. Cell & Gene)

• Why it’s different: Small populations, high uncertainty, and concentrated centers of excellence require granular landscape assessment and tailored stakeholder education.
• Evidence & RWE: Plan for long-term outcomes and establish registries to address uncertainty; align early on what outcomes matter to payers and patients.
• Stakeholders & policy: Expect heavier involvement from policy, advocacy, and government affairs functions than in other archetypes.
• Evolving CGT status: Cell & gene therapies are converging with rare/oncology today but are likely to become a distinct archetype with unique payment and channel models as the field matures.

(this document continues in our next week post)